发明名称 STABLE LIQUID FORMULATION OF BOTULINUM TOXIN
摘要 PROBLEM TO BE SOLVED: To provide a ready-to-use liquid formulation of botulinum toxin that can be conveniently shipped, stored and used as needed.SOLUTION: A composition is for treating a patient in need of inhibition of cholinergic transmission to selected muscle or muscle group or a gland or an organ. The composition contains a stable liquid pharmaceutical botulinum toxin formulation prepared for the use of pharmaceutically effective dosage, the formulation containing: (a) a pharmaceutically acceptable buffered physiological saline containing a buffering component selected from a phosphate buffer solution, a phosphate-citrate buffer solution and succinate buffer solution; (b) serum albumin; and (c) isolated botulinum toxin. The composition is stable as a liquid for at least 1 year at a temperature of ±10% of a temperature between 0°C and 10°C or stable as a liquid for at least 6 months at a temperature of ±10% of a temperature between 10°C and 30°C, and the composition is suitable for the administration as a medicine to mammals without necessitating further reconstitution.
申请公布号 JP2013144691(A) 申请公布日期 2013.07.25
申请号 JP20130039884 申请日期 2013.02.28
申请人 US WORLDMEDS LLC 发明人 MOYER ELIZABETH;HIRTZER PAMELA
分类号 A61K9/08;A61K38/00;A61K8/64;A61K9/00;A61K35/74;A61K38/16;A61K38/48;A61K47/02;A61K47/04;A61K47/12;A61K47/42;A61P1/00;A61P1/02;A61P1/04;A61P1/06;A61P9/00;A61P11/02;A61P11/06;A61P13/06;A61P15/00;A61P15/04;A61P15/06;A61P17/00;A61P19/02;A61P21/00;A61P21/02;A61P25/00;A61P25/02;A61P25/04;A61P25/06;A61P25/08;A61P25/14;A61P25/16;A61P25/28;A61P27/02;A61P27/16;A61P43/00;A61Q19/00;A61Q19/08;C07K4/04;C07K14/195 主分类号 A61K9/08
代理机构 代理人
主权项
地址